JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

30.51 0.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

30.51

Максимум

31.15

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+57.59% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	122M 3B
Предишно отваряне	30.08
Предишно затваряне	30.51

Настроения в новините

By Acuity

50%

160 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1.05.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1.05.2026 г., 18:37 ч. UTC

Значими двигатели на пазара

Senseonic Shares Slide on Underwritten Offering Price

1.05.2026 г., 16:46 ч. UTC

Значими двигатели на пазара

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2.05.2026 г., 19:57 ч. UTC

Придобивния, сливания и поглъщания

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2.05.2026 г., 15:24 ч. UTC

Печалби

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2.05.2026 г., 12:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 20:42 ч. UTC

Печалби

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1.05.2026 г., 19:18 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1.05.2026 г., 19:13 ч. UTC

Пазарно говорене

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1.05.2026 г., 18:36 ч. UTC

Печалби

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 18:28 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1.05.2026 г., 18:27 ч. UTC

Пазарно говорене

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1.05.2026 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Barclays Completes Acquisition of Best Egg

1.05.2026 г., 18:04 ч. UTC

Печалби

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1.05.2026 г., 17:43 ч. UTC

Пазарно говорене

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1.05.2026 г., 17:37 ч. UTC

Пазарно говорене

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1.05.2026 г., 17:30 ч. UTC

Пазарно говорене

Печалби

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1.05.2026 г., 17:28 ч. UTC

Пазарно говорене

Печалби

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Печалби

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1.05.2026 г., 17:19 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1.05.2026 г., 16:38 ч. UTC

Пазарно говорене

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1.05.2026 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

57.59% нагоре

12-месечна прогноза

Среден 48.38 USD 57.59%

Висок 80 USD

Нисък 24.18 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

160 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.